Diallyl disulfide (DADS), the main active component of the cancer fighting allyl sulfides found in garlic, has shown potential as a therapeutic agent in various cancers. In conclusion, the present study demonstrates the C/EBPα expression was correlated with CRT expression in vitro and in vivo and the molecular mechanism of DADSinduced leukaemic cell differentiation.
cells through the induction of differentiation. 7 Therefore, the development of novel differentiation inducing drugs for blocking AML is of clinical significance.
Diallyl disulfide (DADS), the main active component of the cancer fighting allyl sulfides found in garlic, was reported to reduce the initiation of carcinogen induced cancers and inhibit the proliferation of various types of cancer cells. 8 Previous studies confirmed that DADS can inhibit the proliferation of human leukaemia cells in vivo in a dose dependent manner. Several studies showed that a small dose of DADS (<1.25 mg/L) can induce human leukaemia cell differentiation, and proteomic analysis suggested that calreticulin (CRT) was involved in DADS mediated induction of differentiation in HL 60 cells. 1, 9 CRT is a multiprocess calcium buffering chaperone of the endoplasmic reticulum that is essential for numerous cellular functions. [10] [11] [12] Some studies have identified increased expression of CRT in many tumour tissues or cells. 13 CCAAT enhancer binding protein-α (C/EBPα) is a basic leucine zipper transcription factor that is crucial for normal neutrophil differentiation. 14 Deregulation of C/EBPα function by genomic mutations, transcriptional, and posttranscriptional suppression, or phosphorylation-dependent inactivation is a common event in subgroups of AML patients. 15, 16 Previous studies have
shown that in some leukaemic cells, the inhibition of C/EBPα transcription and translation level is closely related to CRT. 17 The downregulation of CRT by siRNA can increase the expression of C/EBPα.
These findings suggest that CRT may be an important factor that regulates C/EBPα in leukaemia differentiation. 18 In the present study, we hypothesised that DADS down-regulates CRT and promotes C/EBPα expression in inducing differentiation of human leukaemia cells. These findings may lead to a better understanding of the molecular mechanisms of the down-regulation of CRT in DADS-induced differentiation of leukaemia cells and will provide essential knowledge for the development of differentiation inducers to treat leukaemia.
| MATERIALS AND METHODS

| Cell culture and treatments
HL-60 cells were purchased from Central South University (Hengyang, China) and cultured in RPMI 1640 (Gibco, California, CA, USA) supplemented with 10% heat-inactivated foetal calf serum.
Cultured cells were maintained in 5% CO 2 and humidified air at 37°C. Cell cultures were replaced with fresh medium every 2-3 days.
Cells in logarithmic growing phase were used for experiments. DADS was diluted to 1.25 mg/L in culture medium. N-acetyl-cysteine (NAC) was diluted to 10 mM in culture medium.
| Patient samples and clinical data
Thirty-nine samples were included in our study, with a mean age of 42.6 ± 14.8 years (median, 46 years; range, 13-87 years). We numbered all the samples from 1 to 39. All patients were diagnosed with leukaemia between 2015 and 2016 in the First Affiliated Hospital of University of South China. We tracked the patients' treatment. We detected the patients before and after treatment, respectively. Patient characteristics are presented in Table 3 . The study was approved by the local Human Research Ethics and Animal Care Committees.
| Bone marrow biopsy
Bone marrow aspirate smears from all patients were stained with a Wright-Giemsa preparation. Bone marrow core biopsies were fixed in B5 fixative, rinsed with 10% neutral buffered formalin, and subjected to limited decalcification in RDO Gold Working Solution (Apex Engineering, Aurora, IL, USA) prior to routine processing.
| Small interference RNA
Small interfering RNA (siRNA) transfection reagent, siRNA transfection medium, were purchased from Santa Cruz Biotech-nology (Dallas, TX, USA). Cells were collected through centrifugation and the concentration was adjusted to 1-2 × 10 6 cells/mL. The cells were then washed once with 2 mL siRNA transfection medium. Two various preparations were used: Solution A, consisting of 6 μL CRT siRNA duplex in 100 μL siRNA transfection medium, and solution B, including 6 μL siRNA transfection reagent in 100 μL siRNA transfection medium. Solution A was then directly added to solution B using a pipette, and the solutions were mixed gently and incubated for 30 minutes at room temperature. siRNA transfection medium (0.8 mL) was added to each tube containing the siRNA transfection reagent mixture, and the mixture was overlaid onto cells. Cells were incubated for 5-7 hours at 37°C in a CO 2 incubator, and then 1 mL of normal growth medium containing two times the normal serum amount (8% calf serum) was directly added without removing the transfection mixture. Cells were incubated for an additional 18-24 hours, after which the medium was removed and replaced with fresh normal growth medium. At 24-72 hours, cells were harvested for analysis.
| Flow cytometry analysis
Leucocyte cells were isolated from the patients' blood. Cells were fixed with 4% paraformaldehyde for 15 minutes. After pre-incuba- at room temperature for 30 minutes. Cells were subjected to flow cytometry (FCM) using a flow cytometer. Data were analysed using FlowJo software (Treestar, Ashland, OR, USA).
| Wright and Giemsa staining
The smears were incubated with Wright Stain (1 mL) for 2 minutes and then rinsed with 2.0 mL distilled water or phosphate buffer pH 
| Hematoxylin-eosin staining
Multiple organs, including brain, heart, lungs, liver, kidneys, and spleen, were removed from killed mice at end-point. Tumour tissue sections were fixed in either alcohol or an aldehyde-based fixative and then processed to obtain 5 μm sections and placed on slides. 750 bp used to extract the alcohol. One or two drops of mounting medium were added, and the sections were covered with a cover slip. 
| Immunofluorescence
| RNA immunoprecipitation
To determine CRT and C/EBPα mRNA interaction in HL-60 cells, the 
| Statistical analysis
Results were presented as mean ± SD. All statistical analysis was performed using SPSS 18.0 software (Statistical Product and Service Solutions, Chicago, USA). The differences between groups were analysed by using the two-sample t test and paired t test. The paired t test was used in the pre-treatment and post-treatment groups, the two-sample t test was used in the pre-treatment group and the control group, as well as in the post-treatment group and the control group. The correlation analysis of two variables using linear regression analysis, twosided P < 0.05 values were considered statistically significant. Figure 1A , sample #21 and #23
were diagnosed as AML without maturation (M1) and AML with maturation (M2), respectively. Compared to the control (sample #9), the bone marrow of leukaemia samples showed extremely active granular hyperplasia.
We next examined CRT and C/EBPα expression in leucocyte of clinical samples before and after clinical treatment by FCM immunophenotyping ( Figure 1B) . CRT level was significantly higher and C/EBPα level was significantly lower in the pre-treatment samples compared to controls (P < 0.01; Table 3 We performed similar analyses for CD11b expression (Figure 3C) . CD11b, also known as cluster of differentiation 11b molecule, is expressed on the surface of numerous leucocytes involved in the innate immune system, including monocytes, granulocytes, macrophages, and natural killer cells. [22] [23] [24] We found that while control cells showed low CD11b expression (1.00%), CRT siRNA signifi- 
| DADS impacted the tumour growth and CRT and C/EBPα expression of SCID mice with HL-60 cells engraftment
We next examined the effects of DADS on tumour growth in vivo.
SCID mice were subcutaneously inoculated with HL-60 cells and then divided into four treatment groups: LD DADS, HD DADS, ATRA, and NS (saline). Differentiation therapies using ATRA are highly efficient at treating acute promyelocytic leukaemia (APL), a subtype of AML. 25 Tumour growth in these groups were compared to untreated mice inoculated with HL-60 cells. After 21 days of treatment, the animals were killed and the tumour sizes were determined. Tumour growth was significantly inhibited in the LD DADS, HD DADS, and ATRA respectively, compared to the controls. The tumour sizes of LD DADS, HD DADS, and ATRA groups were significantly smaller than controls (P < 0.05) ( Figure 3B ). As shown in Figure 3C , in the control group, the tumour cells were dense and necrosis was detected. In the LD DADS, HD DADS, and ATRA groups, differentiation was apparent. We performed Western blot analysis of CRT and C/EBPα protein expressions in tumours removed from the mice after treatment and detected a significant decrease of CRT and up-regulation of C/EBPα protein in the LD DADS, HD DADS, and ATRA groups compared to the control group ( Figure 3D and E).
To monitor any possible toxicity arising from the treatment, the mice were weighed twice weekly during the 21 days treatment period, and no significant differences in body weight, food, or water consumption were observed between control and groups during the intervention.
| DADS induced CRT down-regulation and translocation involves the ROS pathway
We previously showed significantly reduced C/EBPα protein level in HL-60 cells with CRT overexpression. Our current data show that DADS reduced CRT expression levels and up-regulated C/EBPα protein levels ( Figure 2B ). ROS are important second messengers in many cellular processes, including differentiation. Some antitumour drugs promote the expression of C/EBPα by increasing the production of ROS in tumour cells and releasing the binding of CRT and C/EBPα mRNA. 26 We thus speculated whether DADS-mediated regulation of CRT and C/EBPα involves ROS and whether CRT directly regulates C/EBPα mRNA.
We first examined the distribution of CRT in HL-60 cells. In control HL-60 cells, CRT was mainly localised in the cytoplasm, but its expression was reduced and CRT translocated to the plasma membrane surface upon DADS treatment ( Figure 4A ). ROS generation is a crucial modulator in a variety of signaling pathways that are associated with autophagy and apoptosis. 27 To measure ROS, we next used DCFH-DA, which is rapidly oxidised to highly fluorescent dichlorofluorescein (DCF) in the presence of ROS. As shown in By trying to identify ROS pathway, we found that the significant ROS production triggered by DADS was largely inhibited by the antioxidant NAC. The data were not shown. HL-60 cells were pretreated with NAC for 1 hour, followed by DADS treatment for various time points. FCM analysis indicated that DADS-induced ROS production was reduced by NAC pre-treatment. Based on these results, we proposed that ROS levels were up-regulated by DADS, resulting in CRT translocation and a possible "eat-me" signal.
Some antitumour drugs release CRT by increasing the production of ROS in tumour cells, phosphorylating PERK/PKR and eIF2α, activating PI3K/AKT pathway, and displacing CRT/Annexin A1 to the cell membrane C/EBPα mRNA binding, promote C/EBPα expression. Our current data suggest that DADS induced CRT translocation, and PERK and PI3K/AKT pathway may be involved in this process. Next we tried to dissect this signal pathway. In addition, we found that the changes in CRT expression and C/EBPα expression triggered by DADS were largely inhibited by NAC treatment (Figure 4D and E).
We also observed that DADS treatment induced PI3K/AKT activation in HL-60 cells ( Figure 4F and G).
| DADS-induced differentiation of HL-60 cells down-regulates CRT and promotes translation of C/ EBPα mRNA
To further examine the relationship between CRT and C/EBPα mRNA, we performed RIP analysis. Our data showed that DADS treatment for 48 hours results in a marked reduction of CRT protein levels ( Figure 5A and B). We performed RIP assay with anti-CRT antibody and cell lysates from the HL-60 cells and found that C/EBPα mRNA was immunoprecipitated by anti-CRT antibody in untreated cells and that IP was reduced in the presence of DADS ( Figure 5C ), which suggests CRT binds and targets C/EBPα mRNA and that DADS treatment reduces this interaction. As shown in Figure 5D and E, we detected the control and treatment group cells, C/EBPα mRNA in the immunoprecipitate was detected by gel electrophoresis. U1 was the intra-group control of the experiment. The result verified RIP. In the control group, the binding of CRT and C/EBPα mRNA reduced the expression of C/EBPα. In the treatment group, DADS down-regulate CRT and transfer it to the cell membrane, the binding between CRT and C/EBPα mRNA was released, the expression level of C/EBPα increased. and plays an important role in cellular proliferation, differentiation, and apoptosis. Given these roles, it is not surprising that CRT function has important implications in health and disease. 9 C/EBPa is an essential transcription factor for myeloid lineage commitment. 33 One of the most studied transcription factors in haematopoiesis is the leucine zipper C/EBPα, which is mainly involved in cell fate decisions for myeloid differentiation. It's involvement in AML is diverse, with patients frequently exhibiting mutations, deregulation of gene expression or alterations in the function of C/EBPα. 34 The down-regulation of CRT by siRNA can increase the expression of C/EBPα.
These findings suggest that CRT may be an important factor that regulates C/EBPα in leukaemia differentiation. Our previous studies demonstrated the down-regulation of CRT during DADS-induced differentiation in HL-60 cells and indicated that CRT was involved in cell proliferation, invasion, and differentiation in DADS-treated HL-60 cells. 1, 10, 35 Numerous studies have demonstrated that CRT could play an essential role in AML cell proliferation and invasion, and therefore may be an important target for AML. [36] [37] [38] At the same time, CRT is an important factor that regulates the differentiation of C/EBPα from leukaemia. 39 In this study, CRT was highly expressed and C/EBPα was expressed in low levels in the pre-treatment AML patient group compared to controls. We also found that C/EBPα expression was negatively correlated with CRT. These data suggest that CRT is closely associated with C Several studies have shown that DADS (<1.25 mg/L) generates ROS and that this effect is important for the induction of differentiation. 6 DADS can induce ROS production, which is often associated with cancer progression. [43] [44] [45] Indeed, we found that intracellular levels of ROS were increased after treatment of HL-60 cells with DADS. We further found that the significant ROS production triggered by DADS was largely inhibited by NAC, and that NAC affected CRT and C/EBPα expression. These results indicated that DADS induced CRT down-regulation and translocation through the ROS pathway.
RNA immunoprecipitation revealed that CRT binds C/EBPα mRNA and likely mediates its degradation by binding the UG-rich element in the 3′ untranslated region of C/EBPα. 46 CRT was mainly localised in the cytoplasm of untreated HL-60 cells, but it translocated to the plasma membrane surface upon DADS treatment. Furthermore, C/EBPα mRNA was immunoprecipitated by anti-CRT antibody, suggesting that C/EBPα is a CRT target gene. Together these data indicate that CRT inhibits C/EBPα mRNA expression and that DADS-mediated differentiation releases CRT inhibition of C/EBPα mRNA expression.
In conclusion, the present study clearly demonstrates the correla- 
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